Aerovate Therapeutics (NASDAQ:AVTE) vs. Petros Pharmaceuticals (NASDAQ:PTPI) Head to Head Contrast

Aerovate Therapeutics (NASDAQ:AVTEGet Rating) and Petros Pharmaceuticals (NASDAQ:PTPIGet Rating) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, institutional ownership, dividends, risk, analyst recommendations, earnings and valuation.

Institutional & Insider Ownership

92.1% of Aerovate Therapeutics shares are held by institutional investors. Comparatively, 6.1% of Petros Pharmaceuticals shares are held by institutional investors. 48.8% of Petros Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Aerovate Therapeutics and Petros Pharmaceuticals’ gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Aerovate Therapeutics N/A N/A -$22.96 million ($24.58) -0.51
Petros Pharmaceuticals $7.81 million 2.25 -$8.99 million ($1.15) -0.74

Petros Pharmaceuticals has higher revenue and earnings than Aerovate Therapeutics. Petros Pharmaceuticals is trading at a lower price-to-earnings ratio than Aerovate Therapeutics, indicating that it is currently the more affordable of the two stocks.


This table compares Aerovate Therapeutics and Petros Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Aerovate Therapeutics N/A -25.25% -21.12%
Petros Pharmaceuticals -53.76% -52.48% -24.57%

Analyst Recommendations

This is a summary of current ratings and price targets for Aerovate Therapeutics and Petros Pharmaceuticals, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aerovate Therapeutics 0 0 5 0 3.00
Petros Pharmaceuticals 0 0 0 0 N/A

Aerovate Therapeutics currently has a consensus price target of $22.67, indicating a potential upside of 82.35%. Given Aerovate Therapeutics’ higher possible upside, equities analysts clearly believe Aerovate Therapeutics is more favorable than Petros Pharmaceuticals.


Aerovate Therapeutics beats Petros Pharmaceuticals on 6 of the 10 factors compared between the two stocks.

Aerovate Therapeutics Company Profile (Get Rating)

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Petros Pharmaceuticals Company Profile (Get Rating)

Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a patented topical formulation candidate for the treatment of acute Peyronie's disease. The company markets its line of ED products in the form of vacuum erection device products. Petros Pharmaceuticals, Inc. is based in New York, New York.

Want More Great Investing Ideas?

Receive News & Ratings for Aerovate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerovate Therapeutics and related companies with's FREE daily email newsletter.